TY - JOUR
T1 - Increased Serum Phospholipase A2 Activity in Advanced Chronic Liver Disease as an Expression of the Acute Phase Response
AU - Pirisi, Mario
AU - Fabris, Carlo
AU - Soardo, Giorgio
AU - Toniutto, Pierluigi
AU - Bartoli, Ettore
AU - Piera Panozzo, Maria
PY - 1993
Y1 - 1993
N2 - Phospholipase A2 (PLA2) modifications were investigated in patients with acute and chronic liver diseases, PLA2 variations were related to indices of liver function as well as to parameters of the acute phase response. Serum PLA2 activity modifications were fluorimetrically measured in 105 patients affected by acute and chronic liver diseases or extra-hepatic diseases. One-way ANOVA demonstrated a significant difference among groups (F = 4.53, P<0.001); Bonferroni’s test for pairwise comparisons showed that patients with hepatocellular carcinoma had higher mean values than subjects with benign extra-hepatic diseases (P<0.01) and mild chronic liver disease (P<0.05). Multiple regression analysis, performed choosing PLA2 as the dependent variable and blood urea nitrogen, C-reactive protein, alkaline phosphatase and α1-fetoprotein as predictor variables was significant (multiple R = 0.7056, multiple R2 = 0.4978, F = 15.36, P = <0.0001). The standardized regression coefficients found to be significant were those of C- reactive protein, blood urea nitrogen and α1-fetoprotein. In conclusion, in patients with chronic liver disease, serum PLA2 activity increases parallel to disease severity and accompanies the expression of proteins of the acute phase response that, like PLA2 activity, increase in serum while liver synthesis declines.
AB - Phospholipase A2 (PLA2) modifications were investigated in patients with acute and chronic liver diseases, PLA2 variations were related to indices of liver function as well as to parameters of the acute phase response. Serum PLA2 activity modifications were fluorimetrically measured in 105 patients affected by acute and chronic liver diseases or extra-hepatic diseases. One-way ANOVA demonstrated a significant difference among groups (F = 4.53, P<0.001); Bonferroni’s test for pairwise comparisons showed that patients with hepatocellular carcinoma had higher mean values than subjects with benign extra-hepatic diseases (P<0.01) and mild chronic liver disease (P<0.05). Multiple regression analysis, performed choosing PLA2 as the dependent variable and blood urea nitrogen, C-reactive protein, alkaline phosphatase and α1-fetoprotein as predictor variables was significant (multiple R = 0.7056, multiple R2 = 0.4978, F = 15.36, P = <0.0001). The standardized regression coefficients found to be significant were those of C- reactive protein, blood urea nitrogen and α1-fetoprotein. In conclusion, in patients with chronic liver disease, serum PLA2 activity increases parallel to disease severity and accompanies the expression of proteins of the acute phase response that, like PLA2 activity, increase in serum while liver synthesis declines.
KW - Acute phase response
KW - Hepatocellular carcinoma
KW - Liver disease
KW - Phospholipase A2
UR - http://www.scopus.com/inward/record.url?scp=0027508410&partnerID=8YFLogxK
U2 - 10.1155/1993/414529
DO - 10.1155/1993/414529
M3 - Article
SN - 0278-0240
VL - 11
SP - 103
EP - 111
JO - Disease Markers
JF - Disease Markers
IS - 2-3
ER -